Navigation Links
Igenica Appoints Thi-Sau Migone, Ph.D., as Chief Scientific Officer
Date:4/9/2013

BURLINGAME, Calif., April 9, 2013 /PRNewswire/ -- Igenica, Inc., an innovative biopharmaceutical company focused on the discovery and development of first-in-class antibody-based therapeutics for the treatment of cancer, today announced the appointment of Thi-Sau Migone , Ph.D., to the role of Chief Scientific Officer.

Dr. Migone brings wide-ranging experience in the discovery and development of novel therapeutic antibodies.  Dr. Migone joins Igenica from Human Genome Sciences, where she held a variety of executive positions and most recently served as Vice President of Research.  In that role, she led scientific programs ranging from early discovery through Biologics License Applications, including belimumab and raxibacumab, two antibody programs that reached regulatory approval under her scientific leadership.  Prior to Human Genome Sciences, Dr. Migone held research positions at DNAX Research Institute, the National Heart, Lung and Blood Institute and National Institute of Allergy and Infectious Diseases.  Dr. Migone received a doctoral degree in Biological Sciences from the University of Pavia, Italy.

"Dr. Migone has a track record of leading and advancing biotherapeutics programs from discovery to successful product approval," said Mary Haak-Frendscho , Ph.D., Chief Executive Officer of Igenica.  "She brings an exceptional skillset and talent to Igenica at a time of great promise for Igenica's platform and first-in-class antibody-based therapeutic programs."

"Igenica has developed an integrated suite of differentiated technologies and capabilities supporting the discovery of novel cancer targets, antibodies and antibody-drug conjugates.  The Company is building a pipeline of next-generation cancer therapeutics that have significant potential to improve outcomes for cancer patients," said Dr. Migone.  "I am delighted to have this opportunity to contribute to Igenica's success."

About Igenica, Inc.

Igenica, Inc. is a biopharmaceutical company pioneering breakthrough antibody-based cancer medicines. The company has integrated innovative technology platforms to address the major challenges to developing effective treatments for multiple oncology indications, with sTAg, a forward-looking proteomics approach to discovering novel tumor antigens, iTAb, a functional in vivo antibody screening approach, and next generation antibody-drug conjugate technology.  Igenica's technology platforms drive innovative drug discovery and promise to identify novel and more effective cancer therapeutics.

Igenica's Board of Directors includes David Goeddel , Ph.D., The Column Group; John Diekman , Ph.D., 5AM Ventures; Mark A. Goldsmith , M.D., Ph.D., Third Rock Ventures; Carl Gordon , Ph.D., CFA, Orbimed Advisors; Mary Haak-Frendscho , Ph.D., Igenica, Inc.; Robert Schreiber , Ph.D., Igenica Founder and Alumni Endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology and Tumor Immunology Program Leader for the Siteman Comprehensive Cancer Center at Washington University School of Medicine.

Contact:
John K. Celebi , MBA
Chief Business Officer
Igenica, Inc.
(650) 231-4320


'/>"/>
SOURCE Igenica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Igenica Closes $33 Million in Series C Funding
2. Igenica Appoints Mary Haak-Frendscho, Ph.D., as Chief Executive Officer
3. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
4. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
5. Nephros Appoints John C. Houghton as President and Chief Executive Officer
6. Elsevier Appoints New President of Elsevier CPM Resource Center
7. GenWay Biotech Appoints New Vice President of Custom/OEM
8. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
9. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Hill-Rom Appoints Alton Shader President of Hill-Rom North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):